Skip to content

Cytek Biosciences, Inc. CTKB Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Danaher logo
DanaherDHR
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA
Bruker logo
BrukerBRKR

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s common stock, par value (in dollars per share)?
Cytek Biosciences, Inc. (CTKB) reported common stock, par value (in dollars per share) of $0 in Q1 2026.